Alpha 1 Antitrypsin Treatment during Human Ex Vivo Lung Perfusion Improves Lung Function by Protecting Lung Endothelium

The majority of potential donor lungs are not being used. The primary reason for underutilization is the concern for primary graft dysfunction (PGD). There is currently no clinically available therapy for PGD. Alpha 1 antitrypsin (A1AT) is a serine protease inhibitor with anti-inflammatory and cytoprotective properties. We and others have shown benefits of A1AT in small and large animal lung transplant studies. Before performing clinical trials, evidence of therapeutic efficacy in human lungs would be valuable.

Source: The Journal of Heart and Lung Transplantation - March 31, 2020 Category: Transplant Surgery Authors: A. Mariscal, A. Nykanen, J. Tikkanen, A. Ali, S. Soltanieh, A. Duong, M. Galasso, S. Juvet, T. Martinu, M. Cypel, M. Liu, S. Keshavjee Tags: (154) Source Type: research